- Conditions
- Glioblastoma, Adult
- Interventions
- Multiple dose of EO2401
- Biological
- Lead sponsor
- Enterome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Herpes Simplex
- Interventions
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Solid Tumor
- Interventions
- AT03-65
- Drug
- Lead sponsor
- Axcynsis Therapeutics Pte Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • Portland, Oregon + 1 more
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 765128, Sham comparator
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1310, Trastuzumab, Osimertinib, capecitabine
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- TORL-2-307-ADC
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Torrance, California + 6 more
- Conditions
- HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
- Interventions
- GQ1001
- Drug
- Lead sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteer
- Interventions
- MT-201, Placebo
- Drug
- Lead sponsor
- Mirador Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Advanced Solid Tumor, Colorectal Cancer
- Interventions
- TORL-3-600
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Fullerton, California • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Solid Tumor
- Interventions
- MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Safety Issues, Tolerance
- Interventions
- FC-12738, Saline
- Drug
- Lead sponsor
- Neurodegenerative Disease Research Inc
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Berlin, New Jersey
- Conditions
- Pulmonary Embolism
- Interventions
- r-tPA, The Bashir™ Endovascular Catheter
- Drug · Device
- Lead sponsor
- Thrombolex, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Indianapolis, Indiana • New York, New York + 2 more
- Conditions
- Obesity and Overweight
- Interventions
- NNC0165-1875, Placebo (NNC0165-1875), Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
- Interventions
- CX-2029
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- BMS-986506, Pumitamig, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- REGN13089-M404-M2980
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Huntersville, North Carolina
- Conditions
- Autoimmune Diseases, Multiple Sclerosis
- Interventions
- LPX-TI641
- Drug
- Lead sponsor
- LAPIX Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Dilworth, Minnesota
- Conditions
- Mesial Temporal Lobe Epilepsy
- Interventions
- AAV9-hSyn1-miGRIK2
- Genetic
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Interventions
- ABBV-184
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Fort Wayne, Indiana • Canton, Ohio • Philadelphia, Pennsylvania
- Conditions
- Solid Tumors (Phase 1)
- Interventions
- ADCE-B05
- Drug
- Lead sponsor
- Adcendo ApS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Springdale, Arkansas • New Haven, Connecticut • Houston, Texas
- Conditions
- Graves Disease
- Interventions
- MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
- Biological
- Lead sponsor
- Merida Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
- Conditions
- HIV
- Interventions
- 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
- Conditions
- HIV Infections
- Interventions
- Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Lenexa, Kansas • Las Vegas, Nevada • Austin, Texas + 2 more
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Interventions
- AV-001, Placebo
- Drug · Other
- Lead sponsor
- Vasomune Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio